While these medications are changing lives, they are not magic injections
MLAGA, Spain Semaglutide (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation well before patients achieve substantial weight loss or reach the full 2.4 mg weekly dose according to new data from the SELECT trial
Generally speaking, your risk of developing erectile problems are likely less when taking a GLP-1, especially after your body builds normal tolerance
Managing multiple prescriptions can feel overwhelming, but with the right strategies, you can minimize risks and maintain your health
After projected FDA approval in 2027 to 2028, the MHRA typically follows within 6 to 12 months
Retrieved on August 04, 2026 from MLA Pramanik, Priyanjana